John C Reed is EVP, Innovative Medicine, R&D of JOHNSON & JOHNSON. Currently has a direct ownership of 29,795 shares of JNJ, which is worth approximately $4.63 Million. The most recent transaction as insider was on May 01, 2025, when has been sold 11,002 shares (Common Stock) at a price of $156.31 per share, resulting in proceeds of $1,719,722. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 29.8K
91.71% 3M change
157.36% 12M change
Total Value Held $4.63 Million

JOHN C REED Transaction History

Date Transaction Value Shares Traded Shares Held Form
May 01 2025
SELL
Payment of exercise price or tax liability
$1,719,722 $156.31 p/Share
11,002 Reduced 26.97%
29,795 Common Stock
May 01 2025
BUY
Exercise of conversion of derivative security
-
25,255 Added 38.24%
40,797 Common Stock
Feb 18 2025
SELL
Payment of exercise price or tax liability
$60,117 $156.15 p/Share
385 Reduced 2.42%
15,542 Common Stock
Feb 15 2025
BUY
Exercise of conversion of derivative security
-
1,350 Added 7.81%
15,927 Common Stock
May 01 2024
SELL
Payment of exercise price or tax liability
$1,588,176 $144.59 p/Share
10,984 Reduced 48.69%
11,577 Common Stock
May 01 2024
BUY
Exercise of conversion of derivative security
-
22,255 Added 49.66%
22,561 Common Stock
JCR

John C Reed

EVP, Innovative Medicine, R&D
New Brunswick, NJ

Track Institutional and Insider Activities on JNJ

Follow JOHNSON & JOHNSON and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells JNJ shares.

Notify only if

Insider Trading

Get notified when an Johnson & Johnson insider buys or sells JNJ shares.

Notify only if

News

Receive news related to JOHNSON & JOHNSON

Track Activities on JNJ